Everything below concerns Preclinical study. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-04-28. Numbers and descriptions here follow the published literature rather than marketing material.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV; not a natural hormone. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Naming conventions differ across vendors and papers. |
| CAS Registry Number | 1401708-83-6 | Listed in some chemical databases; verify against primary sources. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Solubility | Soluble in DMSO; limited in water | Organic stock solutions are common in laboratory settings. |
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
=== Familia Neo/323C/323 Neo === The Familia Neo started production for the Japanese domestic market in 1994 (axed in 1996), and was also sold as the 323C in Europe and the 323 in Canada. Ford released a rebadged version which was mechanically the same although different bumpers, headlights and bonnet were fitted, badged as the Ford Laser Lynx in Japan and Australia, and the Ford Aztec in Taiwan. This model was only available as the Ford Laser Lynx in the Australian market, as Mazda already had the 323 Astina Hatch filling the gap for a hatchback in the Mazda range. To contradict this, Mazda Australia also offered two 323 saloons, the Astina/Lantis hardtop and the 323 Protegé until production of both models ceased in 1998. It featured a rear hatch with a divided glass, much like the Honda CR-X. Aesthetically the Familia Neo was very close in looks to a Mazda Lantis/323F and equated to a three-door version and also shared the Lantis suspension. The top specced Familia Neo was fitted with a DOHC 1839 cc BP-ZE engine which produced around 114–135 PS (84–99 kW) (depending on the market), and this was the same engine fitted to the base model Mazda Lantis. It was also sold for a single year (1995) in Canada as 323 GS. In Europe it was named Mazda 323C (for coupé), available for sale until September 1998 and it was equipped with 1.3 L SOHC, 1.5 L DOHC 16V, and 1.8 L DOHC 16V engine.
Jennifer Moyle (1921-2016), British biochemist involved in the development of the chemiosmosic theory Kary Mullis (1944–2019). American biochemist at the Cetus Corporation (Emeryville, California), inventor of the polymerase chain reaction. Nobel Prize in Chemistry (1993).
=== Thirds, fourths === The term "minute" usually means 1⁄60 of an hour, coming from "a minute division of an hour". The term "second" comes from "the second minute division of an hour", as it is 1⁄60 of a minute, or 1⁄60 of 1⁄60 of an hour. While usually sub-second units are represented with SI prefixes on the second (e.g. milliseconds), this system can be extrapolated further, such that a "third" would mean 1⁄60 of a second (16.7 milliseconds), and a "fourth" would mean 1⁄60 of a third (278 microseconds), etc. These units are occasionally used in astronomy to denote angles.
==== Consumers ==== Single cross-sectional studies on consumers have been published noting multiple associations. Blood serum levels of PFOA were associated with an increased time to pregnancy—or "infertility"—in a 2009 study. PFOA exposure was associated with decreased semen quality, increased serum alanine aminotransferase levels, and increased occurrence of thyroid disease. In a study of 2003–2004 US samples, a higher (9.8 milligram per deciliter) total cholesterol level was observed when the highest quartile was compared to the lowest. Along with other related compounds, PFOA exposure was associated with an increased risk of attention deficit hyperactivity disorder (ADHD) in a study of US children aged 12–15. In a paper presented at the 2009 annual meeting of the International Society of Environmental Epidemiology, PFOA appeared to act as an endocrine disruptor by a potential mechanism on breast maturation in young girls. A C8 Science Panel status report noted an association between exposure in girls and a later onset of puberty.
=== Book bans === In May 2023, during a commencement speech at Morehouse College, Moore criticized efforts to ban books and restrict curriculum in schools, suggesting that politicians who sought to "silence or rewrite the history of Black and brown people are actually afraid of people understanding their power". In April 2024, Moore signed into law the Freedom to Read Act, which prohibits public and school libraries from banning books based on partisan, ideological, or religious reasons, or based an author's origin, background, or views.
Sources: en.wikipedia.org
The University of Pittsburgh Medical Center (UPMC) is an American integrated global nonprofit health enterprise that has 100,000 employees, 40 hospitals with more than 8,000 licensed beds, 800 clinical locations including outpatient sites and doctors' offices, a 3.8 million-member health insurance division, as well as commercial and international ventures. It is closely affiliated with its academic partner, the University of Pittsburgh. It is considered a leading American health care provider, as its flagship facilities have ranked in U.S. News & World Report "Honor Roll" of the approximately 15 to 20 best hospitals in the U.S. for over 15 years. As of 2016, its flagship hospital UPMC Presbyterian was ranked 12th nationally among the best hospitals (and first in Pennsylvania) by U.S. News & World Report and ranked in 15 of 16 specialty areas when including UPMC Magee-Womens Hospital. This does not include UPMC Children's Hospital of Pittsburgh which ranked in the top 10 of pediatric centers in a separate US News ranking.
=== Global shortages === Morphine and other poppy-based medicines have been identified by the World Health Organization as essential in the treatment of severe pain. As of 2002, seven countries (USA, UK, Italy, Australia, France, Spain and Japan) use 77% of the world's morphine supplies, leaving many emerging countries lacking in pain relief medication. The current system of supply of raw poppy materials to make poppy-based medicines is regulated by the International Narcotics Control Board under the provision of the 1961 Single Convention on Narcotic Drugs. The amount of raw poppy materials that each country can demand annually based on these provisions must correspond to an estimate of the country's needs taken from the national consumption within the preceding two years. In many countries, underprescription of morphine is rampant because of the high prices and the lack of training in the prescription of opiates. The World Health Organization is now working with administrations from various countries to train healthcare workers and to develop national regulations regarding drug prescription to facilitate a greater prescription of opiates.
κ-Bungarotoxin can be extracted from the Bungarus multicinctus venom glands. Upon extraction, the κ-bungarotoxin needs to be isolated and purified for further use. Another way to yield κ-bungarotoxin is by chemically synthesizing the gene which codes for the toxin. Transplanting this gene into Escherichia coli does not result in a stable product. However, after fusing the toxin with rat intestinal fatty acids, the fusion proteins differed only in cleavage sites. Hereafter, the κ-bungarotoxin could be isolated and purified. Further research discovered that an active form of yeast, Pichia pastoris, was able to make biologically active Kappa-Bungarotoxin. This process does not require additional manipulation of genes or proteins. Furthermore, the produced quantity is five times higher than that of E. coli produced κ-bungarotoxin.
=== Flower press === This floral preservation has its roots in Victorian times, but has also been brought into the current list of Floral Preservation because of new techniques of pressing, vacuum sealing and color enhancing. This method uses a "flower press" that sandwiches the flower between two rigid layers, often lined with a breathable/adsorbent fabric to allow moisture to leave the flower, then applies a small amount of pressure to the flower, allowing it to keep its shape while it dries. The art is then framed in a flat shadow box style frame, to hang on the wall. Vacuum sealing the art is recommended and the use of Museum Quality glass with a UV Factor of 97% to ensure the colors last.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.
No. Dihexa shares a conceptual link to angiotensin IV but has different structural features. Those changes are intended to modify its behavior in biological systems.
It often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. Synonyms and CAS listings vary, so cross-checking identifiers is necessary.
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.